Study is not a clinical trial for ALS.

Study is not randomised.

Intervention is not a pharmaceutical drug, cell therapy, or supplement.

Study does not report clinical efficacy outcomes.

Study is not the primary report of the trial (ie, a post hoc analysis).

The randomised period is shorter than 12 weeks.

Randomised population consists of fewer than 20 patients.

Study has a deviating design (fully open-label, cross-over, historically controlled).

Patient enrolment started before 1999.

Study is a phase I or IV trial.

Study is a systematic review for ALS.

Study summarises clinical trial evidence of disease-modifying therapies.